OVO

ThoughtSpot Named Google Cloud Technology Partner of the Year for Data - Business Intelligence

Retrieved on: 
화요일, 4월 9, 2024
Cloud, OVO, Google Workspace Marketplace, Google Cloud, Organization, Ishikawa diagram, Software as a service, OVO Energy, Bed sheet, Data analysis, Partnership, Health, The Algorithm, Data, KPI, AI, ThoughtSpot, Anomaly, Human, PostgreSQL, CVS Health, CNA Financial, Investment, Creativity, Sage, Looker, Machine learning, Wells Fargo, Corporation, Network equipment provider

MOUNTAIN VIEW, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- ThoughtSpot , the AI-Powered Analytics company, today announced it has been named the 2024 Google Cloud Technology Partner of the Year Award for Data – Business Intelligence.

Key Points: 
  • MOUNTAIN VIEW, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- ThoughtSpot , the AI-Powered Analytics company, today announced it has been named the 2024 Google Cloud Technology Partner of the Year Award for Data – Business Intelligence.
  • With ThoughtSpot and Google Cloud, companies around the world are transforming data into actionable insights across their organization, maximizing the value of their cloud investments as they put GenAI to work for their business.
  • ThoughtSpot SaaS is available on Google Cloud Marketplace, the BigQuery Partner Center, and Google Workspace Marketplace.
  • "We're proud to announce ThoughtSpot as a 2024 Google Cloud Partner Award winner and recognize their achievements enabling customer success from the past year.”

Summary of opinion: Prevexxion RN+HVT+IBD, 13/03/2024 Positive

Retrieved on: 
수요일, 4월 3, 2024
OVO, European Commission, Civil service commission, European Medicines Agency, Committee, Marketing, SPC, UPD, CVMP

On 13 March 2024 the Committee for Veterinary Medicinal Products (CVMP) adopted a positive opinion1, recommending the granting of a variation to the terms of the marketing authorisation for the veterinary medicinal product Prevexxion RN+HVT+IBD.

Key Points: 
  • On 13 March 2024 the Committee for Veterinary Medicinal Products (CVMP) adopted a positive opinion1, recommending the granting of a variation to the terms of the marketing authorisation for the veterinary medicinal product Prevexxion RN+HVT+IBD.
  • The marketing authorisation holder for this veterinary medicinal product is Boehringer Ingelheim Vetmedica GmbH.
  • Prevexxion RN+HVT+IBD is currently authorised as concentrate and solvent for suspension for injection.
  • The variation concerns the addition of a new route of administration: in ovo.

Summary of opinion: Prevexxion RN+HVT+IBD, 13/03/2024 Positive

Retrieved on: 
수요일, 4월 3, 2024
OVO, European Commission, Civil service commission, European Medicines Agency, Committee, Marketing, SPC, UPD, CVMP

On 13 March 2024 the Committee for Veterinary Medicinal Products (CVMP) adopted a positive opinion1, recommending the granting of a variation to the terms of the marketing authorisation for the veterinary medicinal product Prevexxion RN+HVT+IBD.

Key Points: 
  • On 13 March 2024 the Committee for Veterinary Medicinal Products (CVMP) adopted a positive opinion1, recommending the granting of a variation to the terms of the marketing authorisation for the veterinary medicinal product Prevexxion RN+HVT+IBD.
  • The marketing authorisation holder for this veterinary medicinal product is Boehringer Ingelheim Vetmedica GmbH.
  • Prevexxion RN+HVT+IBD is currently authorised as concentrate and solvent for suspension for injection.
  • The variation concerns the addition of a new route of administration: in ovo.

Canada Goose Reports Third Quarter Fiscal 2024 Results

Retrieved on: 
목요일, 2월 1, 2024
Retail, Luxury, Fashion, Black Friday, American Dream, Travel, DTC, OVO, Giant, Tax, Bank statement, Acquisition, Risk, BAPE, Toronto Stock Exchange, Shoe, Security (finance)

Notable business highlights from our third quarter included the following:

Key Points: 
  • Notable business highlights from our third quarter included the following:
    Launched our second collaboration with BAPE, which has been the fastest selling collaboration year-to-date in fiscal 2024.
  • Expanded our travel retail footprint, entering South Korea, following the opening of the travel retail store in Frankfurt in the second quarter of fiscal 2024.
  • Non-Heavyweight Down category grew year-over-year in the third quarter of fiscal 2024, expanding its share of revenue within the overall mix.
  • Based on quarter-to-date trends, Canada Goose expects the following for fourth quarter fiscal 2024:
    Total revenue between $310m and $330m.

EasyRx Now Integrates with 3DISC, Offering Seamless Digital Lab Prescription Workflow

Retrieved on: 
수요일, 11월 15, 2023
Data Management, Health, Technology, Health Technology, Software, Dental, General Health, Dentist, Scan, Tell, Heron, Partnership, OVO, Orthodontics, Dentistry, 3D printing

EasyRx, a leader in universal lab prescription , digital workflow, and 3D software for dentists and orthodontists, is pleased to announce a collaboration with 3DISC, a pioneer in digital dentistry and intraoral scanning solutions.

Key Points: 
  • EasyRx, a leader in universal lab prescription , digital workflow, and 3D software for dentists and orthodontists, is pleased to announce a collaboration with 3DISC, a pioneer in digital dentistry and intraoral scanning solutions.
  • In response to user demand, this partnership brings 3DISC's Heron and OVO IOS technology into the EasyRx digital workflow.
  • Todd Blankenbecler, general manager of EasyRx, shares his thoughts on the new alliance: “We're delighted to partner with 3DISC, a company committed to advancing digital dentistry.
  • Through this integration, EasyRx continues its mission to modernize the entire lab prescription management process for dentists and orthodontists.

Trust Wallet and Alchemy Pay Partner for Seamless Crypto Ramp Solutions

Retrieved on: 
목요일, 11월 30, 2023
GCash, OVO, Mastercard, Web3, Trust, Fiat, Partnership, Alchemy, Visa, Cryptocurrency, Hong Kong

SINGAPORE, Nov. 29, 2023 /PRNewswire/ -- Alchemy Pay, the leading fiat-crypto payment solution provider, has announced a new partnership with Trust Wallet, the leading self-custody and mutichain wallet with over 70 million users, enabling users to easily buy and sell crypto with multiple fiat payments within Trust Wallet directly.

Key Points: 
  • SINGAPORE, Nov. 29, 2023 /PRNewswire/ -- Alchemy Pay, the leading fiat-crypto payment solution provider, has announced a new partnership with Trust Wallet, the leading self-custody and mutichain wallet with over 70 million users, enabling users to easily buy and sell crypto with multiple fiat payments within Trust Wallet directly.
  • "Alchemy Pay takes great pride in our partnership with Trust Wallet, one of the leading crypto wallets, to provide comprehensive on and off-ramp support to a global user community.
  • Trust Wallet Product Lead Nate Zou stated: "We're excited to offer more fiat solutions for our users by working with Alchemy Pay, making crypto more accessible than ever.
  • Alchemy Pay specializes in providing solutions that enable cryptocurrency and Web3 services to access fiat payment options, thus enhancing their accessibility for a broader audience.

Canada Goose Reports Second Quarter Fiscal 2024 Results

Retrieved on: 
목요일, 11월 2, 2023
Retail, Luxury, Fashion, Gossypium, National Transformation Program 2020 (Saudi Arabia), Waistcoat, System, Tax, Pressure, Polo neck, Clothing, Concept, Frankfurt Airport, EBIT, Environment, Garnet, Growth, Travel, Risk, OVO, Hong Kong Fashion Week for Fall/Winter, Partnership, Bank statement, BAPE, Lumina, Woman, DTC, Collection, Pharmaceutical industry, Tourism, Wool, Telescopic sight, Security (finance)

Inventory was $519.7m for the second quarter ended October 1, 2023, up 2% from the second quarter ended October 2, 2022, with decelerating year-over-year growth compared to the first quarter of fiscal 2024.

Key Points: 
  • Inventory was $519.7m for the second quarter ended October 1, 2023, up 2% from the second quarter ended October 2, 2022, with decelerating year-over-year growth compared to the first quarter of fiscal 2024.
  • During the second quarter of fiscal 2024, the Company repurchased 1,364,542 subordinate voting shares for a total cash consideration of $29.9m, ending the quarter with a cash balance of $37.5m, compared with $97.1m at first quarter ended October 2, 2022.
  • Non-Heavyweight Down category grew year-over-year in the second quarter of fiscal 2024, expanding its share of revenue within the overall mix.
  • As a result, we saw early momentum gathered in our second quarter of fiscal 2024 begin to slow noticeably in September.

eBay Opens Authentic Streetwear Store on Canal Street in NYC

Retrieved on: 
목요일, 11월 2, 2023
Yeezy, Versace, Bootleg, Shoe, Prada, MCM, MSCHF, Chanel, Adidas, Chrome Hearts, Acquisition, Puma, Nike, Y-3, Canal Street, Kith, Dolce & Gabbana, Supreme, Burberry, OVO, Cactus Plant Flea Market, Fendi, BAPE, EBay, Running, Salomon, Shades of white, Clothing, Comme des Garçons, Converse, Online shopping, Fashion design, Asics, New Balance, Reebok, Visvim, Crocs, Givenchy, Vans

NEW YORK, Nov. 2, 2023 /PRNewswire/ -- Today, eBay announces the launch of "Canal Street Wear," a retail shop in NYC with an unrivaled selection of authentic streetwear and sneakers from top eBay sellers. Shoppers will have access to authentic items from the most popular and coveted brands, verified by eBay Authenticity Guarantee – the marketplace's authentication service that recently expanded to streetwear.

Key Points: 
  • Shoppers will have access to authentic items from the most popular and coveted brands, verified by eBay Authenticity Guarantee – the marketplace's authentication service that recently expanded to streetwear.
  • Canal Street Wear brings eBay's incredible selection of authentic streetwear into the hands of shoppers on Manhattan's infamous Canal Street – a longtime hub for bootleg, counterfeit and gray-market goods.
  • Canal Street Wear's merchandise was curated from top rated eBay sellers NYMilan , RIF and Soled Out Jersey City .
  • Shoppers can visit Canal Street Wear (331 Canal Street) on November 3 and 4, from 12 pm - 7 pm ET.

Gaming Lifestyle Powerhouse XSET Signs Esports Phenom and Creator Clix

Retrieved on: 
수요일, 10월 11, 2023
Partnership, Fortnite World Cup, CCO, OVO, Clothing, Gen, Connecting rod, Clix, Sony, Supreme, VF Corporation, XSET, CMO, Growth, Nike, Wolf, The Wolf of Wall Street, Esports, Wall Street, Generation Z, Pusha T, Gary Vaynerchuk, Pedigree, Diplo, Karmaloop, Sport, Video game, Adidas, Fortnite, Vans, Diesel

LOS ANGELES, Oct. 11, 2023 /PRNewswire/ -- XSET, the world's fastest-growing gaming lifestyle brand, is thrilled to announce the signing of celebrated Fortnite Pro Player, Twitch Streamer, and creator of clothing brand Dr3amin, Cody "Clix" Conrod. More than a traditional signing, this groundbreaking, multi-year partnership represents a novel strategic alliance between gaming and lifestyle, further solidifying XSET's presence in both the Fortnite realm and in fashion.

Key Points: 
  • LOS ANGELES, Oct. 11, 2023 /PRNewswire/ -- XSET, the world's fastest-growing gaming lifestyle brand, is thrilled to announce the signing of celebrated Fortnite Pro Player, Twitch Streamer, and creator of clothing brand Dr3amin, Cody "Clix" Conrod.
  • Fast forward four years, and at 18 years old, Clix has risen to become the most-watched Fortnite streamer on Twitch while also ranking as the 27th most-followed creator.
  • At the announcement of the agency signing, Vaynerchuk called Clix the embodiment of "what the gaming creator economy is all about."
  • Cody "Clix" Conrod's journey continues to push the boundaries of gaming and esports, and this partnership with XSET redefines what is possible in the world of competitive gaming and lifestyle.

Brenus Pharma unveils promising pre-clinical results extrapolating human conditions in major international congresses.

Retrieved on: 
목요일, 9월 28, 2023
Oncology, Health, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, Mouse, Clinical trial, Entrepreneurship, OVO, Pharming, STC, Vaccine

Benoit PINTEUR, (Pharm.D), Co-Founder and Chief Scientific Officer at Brenus Pharma explains: "After testing the STC product on colorectal cancer models in syngeneic immunocompetent mice (in vivo), where results have shown improved overall survival and enhanced immune response with STC-1010, we tested new models (ex vivo, in ovo) to enhance human extrapolation to validate the STC-1010 biological mechanism of action and replicate excellent results on human colorectal cancer models.

Key Points: 
  • Benoit PINTEUR, (Pharm.D), Co-Founder and Chief Scientific Officer at Brenus Pharma explains: "After testing the STC product on colorectal cancer models in syngeneic immunocompetent mice (in vivo), where results have shown improved overall survival and enhanced immune response with STC-1010, we tested new models (ex vivo, in ovo) to enhance human extrapolation to validate the STC-1010 biological mechanism of action and replicate excellent results on human colorectal cancer models.
  • All our efforts are now focused on regulatory approvals and batch production for the clinical trial in 2024."